{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T14:46:36Z","timestamp":1793285196816,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Liuzhou Science and Technology Program","award":["2020NBAD0801"],"award-info":[{"award-number":["2020NBAD0801"]}]},{"name":"Liuzhou Science and Technology Program","award":["2020NBAD0801"],"award-info":[{"award-number":["2020NBAD0801"]}]},{"name":"Liuzhou Science and Technology Program","award":["2020NBAD0801"],"award-info":[{"award-number":["2020NBAD0801"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Antiretroviral therapy (ART) has transformed HIV management, with various regimens available. Dolutegravir (DTG) plus lamivudine (3TC) dual therapy is now the one of the first line regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective, observational study included treatment na\u00efve people living with HIV (PLWH) with baseline HIV RNA viral load (VL) greater than 500,000 copies\/mL from March 2020 to June 2022. PLWH on DTG\u2009+\u20093TC were included in the 2DR group, while others on INSTI-based three-drug regimens were divided in the 3DR group. Viral suppression, immunological recovery, and safety were assessed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 52 PLWH, with no significant baseline differences. Virologic suppression rates at weeks 24 and 48 were similar in both groups, even with baseline HIV RNA VL greater than 1,000,000 copies\/mL. CD4\u2009+\u2009T cell counts improved rapidly. No serious adverse effects were reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DTG\u2009+\u20093TC dual therapy demonstrates effectiveness in treatment na\u00efve PLWH with high baseline HIV RNA VL, suggesting its potential as a first line regimen for all treatment na\u00efve PLWH.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-024-09624-2","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T12:02:15Z","timestamp":1721649735000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["DTG\u2009+\u20093TC dual therapy for the treatment Na\u00efve patients with viral load exceeding 500,000 copies\/mL: a retrospective study"],"prefix":"10.1186","volume":"24","author":[{"given":"Yanyun","family":"Dou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangfu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruichao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingsong","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihao","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanfang","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanlong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuanglai","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"9624_CR1","doi-asserted-by":"publisher","first-page":"207","DOI":"10.4414\/smw.2001.06132","volume":"131","author":"M Flepp","year":"2001","unstructured":"Flepp M, Schiffer V, Weber R, Hirschel B. Modern anti-HIV therapy. Swiss Med Wkly. 2001;131:207\u201313. https:\/\/doi.org\/10.4414\/smw.2001.06132.","journal-title":"Swiss Med Wkly"},{"key":"9624_CR2","unstructured":"WHO, CONSOLIDATED GUIDELINES ON HIV PREVENTION TESTING, TREATMENT, SERVICE DELIVERY AND MONITORING. : RECOMMENDATIONS FOR A PUBLIC HEALTH APPROACH. 2021."},{"key":"9624_CR3","unstructured":"DHHS. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. 2022."},{"key":"9624_CR4","unstructured":"EACS. European aids clinical society guidelines. 2022."},{"key":"9624_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1001\/jama.2022.22246","volume":"329","author":"RT Gandhi","year":"2023","unstructured":"Gandhi RT, Bedimo R, Hoy JF, Landovitz RJ, Smith DM, Eaton EF, Lehmann C, Springer SA, Sax PE, Thompson MA, et al. Antiretroviral Drugs for Treatment and Prevention of HIV infection in adults: 2022 recommendations of the International Antiviral Society-USA panel. JAMA. 2023;329:63\u201384. https:\/\/doi.org\/10.1001\/jama.2022.22246.","journal-title":"JAMA"},{"key":"9624_CR6","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/s0140-6736(18)32462-0","volume":"393","author":"P Cahn","year":"2019","unstructured":"Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393:143\u201355. https:\/\/doi.org\/10.1016\/s0140-6736(18)32462-0.","journal-title":"Lancet"},{"key":"9624_CR7","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/qad.0000000000003070","volume":"36","author":"P Cahn","year":"2022","unstructured":"Cahn P, Sierra Madero J, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, et al. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection. Aids. 2022;36:39\u201348. https:\/\/doi.org\/10.1097\/qad.0000000000003070.","journal-title":"Aids"},{"key":"9624_CR8","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11904-019-00478-x","volume":"17","author":"W Cao","year":"2020","unstructured":"Cao W, Hsieh E, Li T. Optimizing treatment for adults with HIV\/AIDS in China: successes over two decades and remaining challenges. Curr HIV\/AIDS Rep. 2020;17:26\u201334. https:\/\/doi.org\/10.1007\/s11904-019-00478-x.","journal-title":"Curr HIV\/AIDS Rep"},{"key":"9624_CR9","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1186\/s12879-018-3158-x","volume":"18","author":"H Tang","year":"2018","unstructured":"Tang H, Mao Y, Tang W, Han J, Xu J, Li J. Late for testing, early for antiretroviral therapy, less likely to die: results from a large HIV cohort study in China, 2006\u20132014. BMC Infect Dis. 2018;18:272. https:\/\/doi.org\/10.1186\/s12879-018-3158-x.","journal-title":"BMC Infect Dis"},{"key":"9624_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12879-021-06991-y","volume":"22","author":"L Deng","year":"2022","unstructured":"Deng L, Li C, Chen P, Luo X, Zheng X, Zhou L, Zhou Y, Xia J, Hong Z. Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection. BMC Infect Dis. 2022;22:17. https:\/\/doi.org\/10.1186\/s12879-021-06991-y.","journal-title":"BMC Infect Dis"},{"key":"9624_CR11","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1097\/qai.0000000000003053","volume":"91","author":"F Zhao","year":"2022","unstructured":"Zhao F, Rao M, Chen W, Cai K, Zhang L, Xu L, Sun L, Liu X, He Y, Wang H. Dolutegravir Plus Lamivudine Dual-Drug Regimen in Treatment-Naive HIV-1-Infected patients with high-level viral load: Preliminary Data from the Real World. J Acquir Immune Defic Syndr. 2022;91:S16\u20139. https:\/\/doi.org\/10.1097\/qai.0000000000003053.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"9624_CR12","doi-asserted-by":"publisher","unstructured":"Gan L, Xie X, Fu Y, Yang X, Ma S, Kong L, Song C, Song Y, Ren T, Long H. Comparison of dolutegravir\u2009+\u2009lamivudine and bictegravir\/emtricitabine\/tenofovir alafenamide in antiretroviral therapy-na\u00efve patients infected with HIV: preliminary results from clinical practice. Expert Rev Anti Infect Ther. 2023;1\u20138. https:\/\/doi.org\/10.1080\/14787210.2023.2279719.","DOI":"10.1080\/14787210.2023.2279719"},{"key":"9624_CR13","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000002907","author":"Y Wei","year":"2023","unstructured":"Wei Y, Li J, Xu R, Wen L, Deng Y, He L, Zhong H, Wang Y. Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir\/emtricitabine\/tenofovir alafenamide in therapy-na\u00efve adults with HIV-1. Chin Med J (Engl). 2023. https:\/\/doi.org\/10.1097\/cm9.0000000000002907.","journal-title":"Chin Med J (Engl)"},{"key":"9624_CR14","doi-asserted-by":"publisher","first-page":"e31100","DOI":"10.1097\/md.0000000000031100","volume":"101","author":"J Li","year":"2022","unstructured":"Li J, Chen D, Wen Z, Du Y, Huang Z, Zhong H, Wang Y, Yin S. Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-na\u00efve HIV-1-infected adults. Med (Baltim). 2022;101:e31100. https:\/\/doi.org\/10.1097\/md.0000000000031100.","journal-title":"Med (Baltim)"},{"key":"9624_CR15","doi-asserted-by":"publisher","first-page":"e0277606","DOI":"10.1371\/journal.pone.0277606","volume":"17","author":"A Cabello-Ubeda","year":"2022","unstructured":"Cabello-Ubeda A, de Quir\u00f3s J, Mart\u00edn Carbonero L, Sanz J, Vergas J, Mena \u00c1, Torralba M, Hern\u00e1ndez Segurado M, Pinto A, Tejerina F, et al. 48-Week effectiveness and tolerability of dolutegravir (DTG)\u2009+\u2009lamivudine (3TC) in antiretroviral-na\u00efve adults living with HIV: a multicenter real-life cohort. PLoS ONE. 2022;17:e0277606. https:\/\/doi.org\/10.1371\/journal.pone.0277606.","journal-title":"PLoS ONE"},{"key":"9624_CR16","doi-asserted-by":"publisher","unstructured":"Evitt LA, Nanji S, Grove RA, Okoli C, van Wyk J, Snedecor SJ. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1. AIDS Res Ther. 2023;20. https:\/\/doi.org\/10.1186\/s12981-023-00507-1.","DOI":"10.1186\/s12981-023-00507-1"},{"key":"9624_CR17","doi-asserted-by":"publisher","first-page":"ofad101","DOI":"10.1093\/ofid\/ofad101","volume":"10","author":"CP Rolle","year":"2023","unstructured":"Rolle CP, Berhe M, Singh T, Ortiz R, Wurapa A, Ramgopal M, Jayaweera DT, Leone PA, Matthews JE, Cupo M, et al. Sustained virologic suppression with Dolutegravir\/Lamivudine in a test-and-treat setting through 48 weeks. Open Forum Infect Dis. 2023;10:ofad101. https:\/\/doi.org\/10.1093\/ofid\/ofad101.","journal-title":"Open Forum Infect Dis"},{"key":"9624_CR18","doi-asserted-by":"publisher","first-page":"1957","DOI":"10.1097\/qad.0000000000002979","volume":"35","author":"CP Rolle","year":"2021","unstructured":"Rolle CP, Berhe M, Singh T, Ortiz R, Wurapa A, Ramgopal M, Leone PA, Matthews JE, Dalessandro M, Underwood MR, et al. Dolutegravir\/lamivudine as a first-line regimen in a test-and-treat setting for newly diagnosed people living with HIV. Aids. 2021;35:1957\u201365. https:\/\/doi.org\/10.1097\/qad.0000000000002979.","journal-title":"Aids"},{"key":"9624_CR19","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1097\/qai.0000000000002302","volume":"84","author":"J Eron","year":"2020","unstructured":"Eron J, Hung CC, Baril JG, Slim J, Falc\u00f3 V, Bogner J, Maggiolo F, Mills A, Sievers J, Man CY, et al. Brief report: Virologic response by baseline viral load with Dolutegravir Plus Lamivudine vs Dolutegravir Plus Tenofovir Disoproxil Fumarate\/Emtricitabine: pooled analysis. J Acquir Immune Defic Syndr. 2020;84:60\u20135. https:\/\/doi.org\/10.1097\/qai.0000000000002302.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"9624_CR20","doi-asserted-by":"publisher","unstructured":"[Chinese guidelines for diagnosis and treatment of HIV\/AIDS. (2021 edition)]. Zhonghua Nei Ke Za Zhi 2021, 60, 1106\u20131128, https:\/\/doi.org\/10.3760\/cma.j.cn112138-20211006-00676.","DOI":"10.3760\/cma.j.cn112138-20211006-00676"},{"key":"9624_CR21","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1111\/j.1365-2125.2012.04440.x","volume":"75","author":"J Koteff","year":"2013","unstructured":"Koteff J, Borland J, Chen S, Song I, Peppercorn A, Koshiba T, Cannon C, Muster H, Piscitelli SC. A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and paraaminohippurate clearance in healthy subjects. Br J Clin Pharmacol. 2013;75:990\u20136. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04440.x.","journal-title":"Br J Clin Pharmacol"},{"key":"9624_CR22","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s40249-020-00668-5","volume":"9","author":"RH Kang","year":"2020","unstructured":"Kang RH, Liang SJ, Ma YL, Liang S, Xiao L, Zhang XH, Lu HY, Xu XQ, Luo SB, Sun XG, et al. Pre-treatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017. Infect Dis Poverty. 2020;9:54. https:\/\/doi.org\/10.1186\/s40249-020-00668-5.","journal-title":"Infect Dis Poverty"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09624-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-09624-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-09624-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T12:02:44Z","timestamp":1721649764000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-09624-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":22,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["9624"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-09624-2","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"5 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee of the Chest Hospital of Guangxi Zhuang Autonomous Region and was conducted in accordance with the Declaration of Helsinki. Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"720"}}